Open: 0.0 Close: 0.0 Change: 0.0

Today's Summary

Medicenna Therapeutics reports second quarter fiscal 2026 financial results and provides a corporate update. Company exits the quarter ended September 30, 2025, with cash and cash equivalents of $15.7 million. Medicenna is a clinical-stage immunotherapy company focused on the development of Superkines. Medicenna Therapeutics reports financial results and corporate highlights for the fiscal year ended March 31, 2025. Company plans to present updated clinical results from both the monotherapy and combination arms of the clinical trial.